Related Experiment Video
Updated: Jan 19, 2026

Characterization of a Pathogenic Escherichia coli Strain Derived from Oreochromis spp. Farms Using Whole-Genome Sequencing
Published on: December 23, 2022
Complete Genome Sequence of Stenotrophomonas maltophilia Podophage Ponderosa
Alejandra Marquez1, Heather Newkirk1, Russell Moreland1
1Center for Phage Technology, Texas A&M University, College Station, Texas, USA.
Abstract:
Stenotrophomonas maltophilia is a Gram-negative bacterium that is emerging as a multidrug-resistant global opportunistic pathogen. Here, we describe the genome of the T7-like S. maltophilia podophage Ponderosa, with 54 predicted protein-coding genes and a 493-bp terminal repeat.
Insights
We sequenced the Ponderosa phage, which infects Stenotrophomonas maltophilia, a multidrug-resistant bacterium. This genome analysis provides insights into phage-host interactions and potential antimicrobial strategies.
Area of Science:
- Microbiology
- Genomics
- Bacteriology
Background:
- Stenotrophomonas maltophilia is a Gram-negative bacterium recognized as a multidrug-resistant opportunistic pathogen.
- The increasing prevalence of multidrug-resistant bacteria necessitates research into novel control mechanisms.
Purpose of the Study:
- To characterize the genome of the T7-like Stenotrophomonas maltophilia podophage Ponderosa.
- To provide genomic data that could inform future therapeutic strategies against S. maltophilia infections.
Main Methods:
- Whole-genome sequencing of the Ponderosa phage.
- Bioinformatic analysis to identify protein-coding genes and genomic features.
Main Results:
- The genome of podophage Ponderosa was fully described.
- The genome contains 54 predicted protein-coding genes.
- A 493-bp terminal repeat was identified in the Ponderosa genome.
Conclusions:
- The genomic characterization of podophage Ponderosa offers a foundation for understanding Stenotrophomonas maltophilia-phage interactions.
- This research contributes to the exploration of phage therapy as a potential alternative to antibiotics for multidrug-resistant infections.

